We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Efficacy and Safety of COVID-19 Vaccine in Patients on Renal Replacement Therapy.
- Authors
Frittoli, Michela; Cassia, Matthias; Barassi, Alessandra; Ciceri, Paola; Galassi, Andrea; Conte, Ferruccio; Cozzolino, Mario Gennaro
- Abstract
Patients with CKD on RRT are at high risk for severe disease and mortality in COVID-19 disease. We decided to conduct an observational prospective study to evaluate antibody response after vaccination for COVID-19 in a cohort of 210 adult patients on RRT (148 on HD; 20 on PD; and 42 kidney transplant recipients). Blood samples were taken before and 4 weeks after vaccination. Antibody levels were evaluated with CLIA immunoassay testing for IgG anti-trimeric spike protein of SARS-CoV-2. A positive antibody titer was present in 89.9% of HD patients, 90% of PD patients, and 52.4% of kidney transplant recipients. Non-responders were more frequent among patients on immunosuppressive therapy. Mycophenolate use in kidney transplant patients was associated with lower antibody response. The median antibody titer was 626 (228–1480) BAU/mL; higher in younger patients and those previously exposed to the virus and lower in HD patients with neoplasms and/or on immunosuppressive therapy. Only two patients developed COVID-19 in the observation period: they both had mild disease and antibody titers lower than 1000 BAU/mL. Our data show a valid response to COVID-19 mRNA vaccination in HD and PD patients and a reduced response in kidney transplant recipients. Mycophenolate was the most relevant factor associated with low response.
- Subjects
COVID-19; RENAL replacement therapy; COVID-19 vaccines; VACCINE safety; ANTIBODY titer
- Publication
Vaccines, 2022, Vol 10, Issue 9, p1395
- ISSN
2076-393X
- Publication type
Article
- DOI
10.3390/vaccines10091395